{"entity":{"id":"nct03259867","kind":"trial","name":"Combination of TATE and PD-1 Inhibitor in Liver Cancer","aka":["TATE-PD1"],"tldr":"A phase 2 trial of Nivolumab in hepatocellular carcinoma, run by Teclison Ltd., now recruiting.","summary":"Combination of TATE and PD-1 Inhibitor in Liver Cancer is a phase 2 interventional study registered as NCT03259867 by Teclison Ltd., with 54 participants planned, started 2017-07-01 and due to reach its primary completion in 2026-12-30. Interventions recorded: Nivolumab Injectable Product, Trans-arterial tirapazamine embolization. Conditions listed: Hepatocellular Carcinoma, Gastric Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03259867","url":"https://clinicaltrials.gov/study/NCT03259867"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["nivolumab"],"companies":["teclison"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03259867","phase":"2","setting":"Phase IIA Single-Arm Study of Treatment of Patients With Advanced Liver Cancer With a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD-1 Monoclonal Antibody","sponsor":"Teclison Ltd.","started":"2017-07-01","startedType":"actual","enrolled":54,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03259867/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"teclison","kind":"company","name":"Teclison","route":"/companies/teclison/"}]}}